FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancerDetection ...
Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...
DALLAS--(BUSINESS WIRE)--Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced ...
Researchers have developed a novel method for simultaneously recording action potentials (APs)—temporary changes in electrical potential when cells become excited—and calcium transients—calcium ...
A research team at National Taiwan University has developed a new stem cell-based vaccine that could help prevent and treat colorectal cancer. Their research demonstrates that iPSC-based vaccines can ...
SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of Good Manufacturing Practices (GMP), cutting-edge, induced pluripotent stem cell (iPSC) technologies, today announced the immediate ...
Human-induced pluripotent stem cells (iPSCs) can be utilized to study complex health conditions in in vitro platforms relevant to humans. It is possible to reprogram human iPSC lines from patient ...
FUJIFILM Cellular Dynamics, Inc., a pioneering global developer and manufacturer of human-induced pluripotent stem cells (iPSCs), today celebrated the opening of its new headquarters and iPSC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results